Cancer Family
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm
CI-CAN-00000039Explore in graph →
Non-malignant864 active trials6 approved drugs159 evidence items
- NCIt
- C35562
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000039Explore in graph →
Clinical trials
3,131 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02658279 | Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype | active not recruiting | N/A | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04737577 | Glioma Supra Marginal Incision Trial(G-SUMIT) | completed | N/A | 44 | Sunnybrook Health Sciences CentreOTHER | 2 | Aug 20, 2026 | clinicaltrials |
| NCT05180825 | Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy(PLGG - MEKTRIC) | recruiting | Phase 2 | 134 | University Hospital, Strasbourg, FranceOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05632562 | Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma | recruiting | Early Phase 1 | 20 | University of Alabama at BirminghamOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05676489 | MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors | not yet recruiting | Early Phase 1 | 28 | University of Alabama at BirminghamOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07775534 | Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma Patients | not yet recruiting | N/A | 30 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02977780 | INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | recruiting | Phase 2 | 460 | David Reardon, MDOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06108206 | Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma | active not recruiting | — | 20 | Columbia UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06556563 | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma(EF-41) | recruiting | Phase 3 | 741 | NovoCure GmbHINDUSTRY | 12 | Aug 19, 2026 | clinicaltrials |
| NCT07762716 | Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy | not yet recruiting | Phase 1 / Phase 2 | 10 | BreakBio CorpINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03173950 | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers | terminated | Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04047264 | Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System Lesions | recruiting | N/A | 100 | Mayo ClinicOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04485559 | Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | recruiting | Phase 1 | 50 | University of California, San FranciscoOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04590235 | A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) | active not recruiting | Phase 1 | 32 | AstraZenecaINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04903795 | BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma(BRiTE) | recruiting | Phase 1 | 18 | Mustafa Khasraw, MBChB, MD, FRCP, FRACPOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06319027 | Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial(GABLE) | recruiting | Phase 2 | 100 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07767110 | Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response(TIGER-1) | not yet recruiting | Phase 1 / Phase 2 | 20 | NanOlogy, LLCINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT07769918 | Hypoxia-targeted Radiotherapy Boost for GBM | not yet recruiting | N/A | 25 | NYU Langone HealthOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04755205 | A Natural History Study of Children and Adults With Olfactory Neuroblastoma | recruiting | — | 525 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05095376 | Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma | active not recruiting | Phase 3 | 265 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT05212272 | MRI in High-Grade Glioma Patients Undergoing Chemoradiation | recruiting | N/A | 16 | Wake Forest University Health SciencesOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05607407 | Methimazole in Patients With Progressive Glioblastoma | suspended | Phase 2 | 19 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05859334 | Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment | active not recruiting | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06492486 | Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow(GLADIATOR) | recruiting | Phase 2 | 60 | Tata Memorial CentreOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06632236 | 5G-EMERALD: Amivantamab in Malignant Brain Tumours(5G-EMERALD) | active not recruiting | Phase 1 | 12 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06894979 | Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma | active not recruiting | Phase 1 | 54 | Children's Oncology GroupNETWORK | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07091864 | Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma | recruiting | N/A | 116 | Mayo ClinicOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07243340 | A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor | recruiting | Phase 1 / Phase 2 | 36 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05650749 | GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma(GPC2) | enrolling by invitation | Phase 1 | 45 | Stephan Grupp MD PhDOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06344130 | Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | recruiting | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06880991 | Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study | recruiting | — | 110 | National Cancer Institute (NCI)NIH | 1 | Aug 14, 2026 | clinicaltrials |
| NCT03389802 | Phase I Study of APX005M in Pediatric Central Nervous System Tumors | completed | Phase 1 | 32 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03871257 | A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma | active not recruiting | Phase 3 | 165 | National Cancer Institute (NCI)NIH | 3 | Aug 13, 2026 | clinicaltrials |
| NCT05450744 | 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)(IPAX-2) | active not recruiting | Phase 1 | 12 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 3 | Aug 13, 2026 | clinicaltrials |
| NCT05476939 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0(BIOMEDE 2) | recruiting | Phase 3 | 433 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 6 | Aug 13, 2026 | clinicaltrials |
| NCT06186401 | Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells | recruiting | Phase 1 | 20 | Hideho Okada, MD, PhDOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06614855 | A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma | active not recruiting | Phase 1 | 12 | James Markert, MDOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07052877 | The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab(GUAVA) | recruiting | — | 20 | Royal North Shore HospitalOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07612917 | Brain Connectivity Changes in Glioma Patients During Treatment(GliRecon) | recruiting | — | 20 | Johannes Kepler University of LinzOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03244995 | Mind-Body Intervention in Glioma Couples | active not recruiting | N/A | 74 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05851378 | Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma | completed | Early Phase 1 | 13 | Robert Bok, MD, PhDOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06161519 | PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications | recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07527169 | A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma | not yet recruiting | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07544992 | Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas | recruiting | Phase 1 | 24 | City of Hope Medical CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT00083512 | Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme | recruiting | — | 200 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03739372 | Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma(PNOC008) | completed | N/A | 44 | University of California, San FranciscoOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04186832 | Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy | active not recruiting | N/A | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04859335 | Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma(EQUI-GAMMA) | recruiting | N/A | 50 | University Hospital, ToulouseOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05057702 | Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma(PNOC027) | recruiting | N/A | 74 | University of California, San FranciscoOTHER | 1 | Aug 11, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 20, 2026source: clinicaltrials